Net Income [USD, thousands]

Share-based Compensation [USD, thousands]

Depreciation and Amortization [USD, thousands]

Amortization of Intangible Assets [USD, thousands]

Amortization of Debt Discount [USD, thousands]

Accretion of (Premium) Discount on Marketable Securities, Net [USD, thousands]

Realized Gain (Loss) on Marketable Securities [USD, thousands]

Loss on Disposal of Equipment [USD, thousands]

Contingent Liability Fair Value Measurement Adjustment [USD, thousands]

Recognition of Deferred Revenue [USD, thousands]

Lease Payments Recognized (Deferred) [USD, thousands]

Induced Conversion Expense Related to Convertible Notes [USD, thousands]

Deferred Income Taxes [USD, thousands]

Other Adjustments [USD, thousands]

Net Cash Provided by Operating Activities [USD, thousands]

Purchases of Marketable Securities [USD, thousands]

Proceeds from Sales and Maturities of Marketable Securities [USD, thousands]

Acquisitions of Business, Net of Cash Acquired [USD, thousands]

Purchases of Property and Equipment [USD, thousands]

Proceeds from Sale of Assets [USD, thousands]

Net Cash Used in Investing Activities [USD, thousands]

Proceeds from Term Loan [USD, thousands]

Proceeds from Revolving Credit Facilities [USD, thousands]

Repayment of 2024 Convertible Notes [USD, thousands]

Payment of Debt Issuance Cost [USD, thousands]

Repurchase of Common Stock [USD, thousands]

Proceeds from Issuance of Common Stock under Equity Incentive Plans, Net of Taxes Paid Related to Net Share Settlement [USD, thousands]

Taxes Paid Related to Net Share Settlement, Net of Proceeds from Issuance of Common Stock under Equity Incentive Plans [USD, thousands]

Net Cash (Used in) Provided by Financing Activities [USD, thousands]

Net (Decrease) Increase in Cash, Cash Equivalents and Restricted Cash [USD, thousands]

Accounts Receivable, Net and Other Contract Assets [USD, thousands]

Inventories [USD, thousands]

Prepaid Expenses and Other Assets [USD, thousands]

Accounts Payable and Accrued Expenses [USD, thousands]

Cash, Cash Equivalents and Restricted Cash at Beginning of Period [USD, thousands]

Cash, Cash Equivalents and Restricted Cash at End of Period [USD, thousands]

de7c34f9dcbfab8db7a68037bc21e8799e8dc165f5c7dc9357224871ef7e52a4

Royalties (USD, thousands)

Product Sales, Net (USD, thousands)

Revenues Under Collaborative Agreements (USD, thousands)

Total Revenues (USD, thousands)

Cost of Sales (USD, thousands)

Amortization of Intangibles (USD, thousands)

Research and Development (USD, thousands)

Selling, General and Administrative (USD, thousands)

Total Operating Expenses (USD, thousands)

Operating Income (USD, thousands)

Investment and Other Income, Net (USD, thousands)

Interest Expense (USD, thousands)

Income Before Income Tax Expense (USD, thousands)

Income Tax Expense (USD, thousands)

Net Income (USD, thousands)

Earnings per Share, Basic (USD)

Earnings per Share, Diluted (USD)

Weighted Average Common Shares Outstanding, Basic (thousands)

Weighted Average Common Shares Outstanding, Diluted (thousands)

dca54f16fa81cb5d2421a4f969afb89fea9518885bb96f9847612acab56385ef

Cash and cash equivalents [USD, thousands]

Marketable securities, available-for-sale [USD, thousands]

Accounts receivable, net and contract assets [USD, thousands]

Prepaid expenses and other current assets [USD, thousands]

Total current assets [USD, thousands]

Property and equipment, net [USD, thousands]

Prepaid expenses and other assets [USD, thousands]

Goodwill [USD, thousands]

Intangible assets, net [USD, thousands]

Deferred tax assets, net [USD, thousands]

Total assets [USD, thousands]

Accounts payable [USD, thousands]

Accrued expenses [USD, thousands]

Total current liabilities [USD, thousands]

Long-term debt, net [USD, thousands]

Other long-term liabilities [USD, thousands]

Total liabilities [USD, thousands]

Common stock - amount [USD, thousands]

Additional paid-in capital [USD, thousands]

Accumulated other comprehensive income (loss) [USD, thousands]

Retained earnings [USD, thousands]

Total stockholders’ equity [USD, thousands]

Total liabilities and stockholders’ equity [USD, thousands]

a911c2308d1452937b18d6003a3dd2b154d590b31e1978a4948e29f9ec880c27

Royalties

Product Sales, Net

- Proprietary Product Sales

- Bulk rHuPH20 Sales

- Device Partnered Product Sales

Revenues Under Collaborative Agreements

- Upfront License and Target Nomination Fees

- Event-Based Development and Regulatory Milestones

- Sales-Based Milestones

- Device Licensing and Development Revenue

Total Revenue

12b6889886299d071c9fca807cdd26131db203361d56863f39e596023afcd35f

Number of total ENHANZE commercial products (products)

Number of ENHANZE commercial products from Roche (products)

Number of ENHANZE commercial products from Takeda (products)

Number of ENHANZE commercial products from Janssen (products)

Number of ENHANZE commercial products from argenx (products)

Number of ENHANZE commercial products from BMS (products)

2f7af90bf822c7c8849cd21028431e0dc1efa3116acba89be5cdd0d269377cb5

United States

Switzerland

Belgium

Japan

All Other Foreign

e9b5d74ac5068eabec123480c76fa44bf77ffe2c3a3ac98e5bd9ca0e39708836

Halozyme Therapeutics Inc (HALO)

Financials